Deciding two connected writ petitions arising from a common Industrial Tribunal Award, the Delhi High Court set aside the Tribunal's direction granting hotel workmen a further…
Helex raises $3.5 mn to develop targeted medicines for genetic kidney diseases
Biotech startup Helex secured $3.5 million to develop targeted therapies for rare genetic kidney diseases. The article explains how Helex’s approach uses genetic research and precision medicine to address underserved medical conditions. The funding will aid R&D, clinical trials, and regulatory clearances. The piece also touches upon investor interest in biotech innovation amid evolving health-tech regulations.